A handful of glucagon-like peptide-1 (GLP-1) agonists have received US Food and Drug Administration (FDA) approval for obesity treatmentincluding liraglutide (Saxenda), semaglutide (Wegovy), and tirzepatide (Zepbound)while others, like exenatide (Byetta, Bydureon), liraglutide (Victoza), semaglutide (Ozempic, Rybelsus), and tirzepatide (again, known as Mounjaro for the diabetes indication), are indicated for type 2 diabetes
This balanced activation contrasts with earlier triple agonist candidates that exhibited suboptimal receptor selectivity profiles or unfavorable safety margins
This is the trap that leads to rapid weight regain if you ever stop the medication
Comparative effectiveness of dulaglutide versus liraglutide in Asian type 2 diabetes patients: a multi-institutional cohort study and meta-analysis
Report any new joint symptoms promptly so they can be assessed and documented appropriately
Choose a time that fits your schedule and stick with it for consistency
